Menu

NECTAR LIFESCIENCES LIMITED (NECLIFE)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality score35 / 100

Profitability 5Growth 1Balance sheet 100

Compare withSUN PHARMACEUTICAL INDUSTRIES DIVIS LABORATORIES TORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹10.25 latest close · −12.8% over the last 90 sessions

₹10.25 month-end · −39.7% over 12 months

₹10.25 month-end · −65.0% over 3 years

₹10.25 month-end · −43.5% since Jan '19

52-week range ₹9.30 to ₹22.40 · 1-year volatility 52.1%

How rough has the ride been?

Maximum drawdown-82.8%not yet recovered

1-year volatility52.1%annualised

Drawdown from peak

Largest drawdowns

-82.8% (2024-09 peak to 2026-03 low, not yet recovered)

-68.5% (2021-07 peak to 2023-03 low, recovered 2024-09)

-63.9% (2019-01 peak to 2020-03 low, recovered 2020-06)

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE9thflat vs a year ago
Op. margin1st▼ 3 pts vs a year ago
Revenue growth1stflat vs a year ago
EPS growth1st
Debt/equity ↓99th▲ 82 pts vs a year ago
Cash cycle ↓39th▲ 5 pts vs a year ago
P/E ↓43rd
12M momentum2nd▼ 4 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

Trailing earnings per share are negative, so a P/E-based figure does not exist. See the loss-makers list on the Expectations Gap page for a revenue-based version.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹10.25
ROCE: 0.0%
Market Cap: ₹199 cr
Revenue (TTM): ₹2 cr
P/S: 99.5x
P/B: 0.3x
ROE: -38.4%
Operating Margin: -6198.0%
Debt / Equity: 0.0x
Promoter Holding: 51.8%
12M Momentum: -39.7%

52-week range

₹9.30₹22.40

7% of the way from its 52-week low to its high

Price risk

1Y volatility

52.1%

Beta vs sector

1-year daily

0.97

Balance sheet & cash

Interest cover

operating profit ÷ interest

-6.9x

Cash from profit, 3Y

operating cash flow ÷ net profit

5.00x

Share count, 1Y

-13.6%

Are profits backed by cash?

2 of 2checks within rangeAll clear

Other income reliance—Not enough data

Not enough reported data to compute this.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion—Not enough data

Not enough reported data to compute this.

Free cash flow4 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 4. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history—Not enough data

Not enough reported data to compute this.

Capital work in progress0% of fixed assetsWithin range

Capital work-in-progress is 0% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 2 years, FIIs trimmed 15.6 pts; promoters trimmed 4.0 pts.
The number of shareholders rose from 60,761 to 73,834 (+22%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change

Promoters55.8%51.8%-4.0 pts

FIIs16.1%0.5%-15.6 pts

DIIs0.0%0.0%0.0 pts

Public and others28.1%43.9%+15.8 pts

Number of shareholders

73,834shareholders+22% since Dec '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−7.6%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like NECTAR LIFESCIENCES LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −22% to +38% vs the market, against −6% for all non-financial companies in the same months.
The gap against the base rate (−1.7%, 80% range −12.3% to +5.7%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 7 beyond the range shown, drawn at the edge

Similar setups' median

−7.6%

All companies' median

−5.9%

Beat the market

44% vs 43%

50 past situations · 50 companies · 38 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
GFLLIMITED Miscellaneous	Aug 2024	—	0%	−4%	−25%	−21%
NILASPACES Consumer Durables	Sep 2023	—	-5%	−9%	−30%	+160%
TAKE Technology Services	Sep 2024	—	-22%	−4%	−39%	−41%
LPDC Finance	Dec 2022	—	-0%	−28%	−51%	−31%
HEXATRADEX Distribution Services	Aug 2025	—	0%	−47%	−52%	−16%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
XELPMOC Technology Services	Jun 2022	—	-18%	−46%	−65%	−57%
AGRITECH Process Industries	Dec 2020	—	-1%	−10%	−23%	+17%
IBULLSLTD Finance	Aug 2022	—	-14%	−43%	−51%	−81%

How reliable is this?

Matched on P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: ROCE, 12-month momentum and interest cover. Not used (unavailable for this company): P/E. This company is loss-making, so it was only compared with loss-making companies. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to NECTAR LIFESCIENCES LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What changed?

25 events since Mar '20

2026
JunPromoterPromoter holding rose 6.9 pts to 51.8%.
JunPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the top quartile).
JunDebtDebt / equity halved over 12 months to 0.00x.
MarPriceFell 83% from the Sep 2024 peak to the Mar 2026 low.
2025
DecPeer rankMoved into the top quartile of Health Technology on operating margin (from the bottom quartile).
JunResultsEPS (TTM) turned negative.
MarPromoterPromoter holding fell 11.3 pts to 44.5%.
2024
DecInstitutionsFII + DII holding fell 13.7 pts over 2 quarters to 3.2%.

Show 17 earlier events

2024
DecPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
SepPriceRegained the 2021-07 peak, 18 months after the low.
JunResultsEPS (TTM) turned positive.
JunValuationP/E crossed above the 90th percentile of its own history to date (136.3x).
2023
JunResultsEPS (TTM) turned negative.
MarPriceFell 68% from the Jul 2021 peak to the Mar 2023 low.
2022
DecValuationP/E crossed above the 90th percentile of its own history to date (21.9x).
JunResultsEPS (TTM) turned positive.
JunValuationP/E crossed above the 90th percentile of its own history to date (20.8x).
2021
JunResultsEPS (TTM) turned negative.
JunPeer rankSlipped to the bottom quartile of Health Technology on ROCE (from the 3rd quartile).
JunDividendDividend payout cut from 4% to 0% of profit.
MayPriceRegained the 2020-06 peak, 6 months after the low.
AprValuationP/E crossed above the 90th percentile of its own history to date (17.6x).
2020
NovPriceFell 40% from the Jun 2020 peak to the Nov 2020 low.
JunPriceRegained the 2019-01 peak, 3 months after the low.
MarPriceFell 64% from the Jan 2019 peak to the Mar 2020 low.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	—	₹2 cr	-38.4%	0.0%	0.0x
2026-10	—	₹2 cr	-38.4%	0.0%	0.0x
2026-09	—	₹2 cr	-38.4%	0.0%	0.0x
2026-08	—	₹7 cr	-45.9%	0.0%	0.0x
2026-07	—	₹7 cr	-45.9%	0.0%	0.0x
2026-06	—	₹7 cr	-45.9%	0.0%	0.0x
2026-05	—	₹6 cr	-33.8%	0.0%	0.6x
2026-04	—	₹6 cr	-33.8%	0.0%	0.6x
2026-03	—	₹6 cr	-33.8%	0.0%	0.6x
2026-02	—	₹6 cr	-34.4%	0.0%	0.6x
2026-01	—	₹6 cr	-34.4%	0.0%	0.6x
2025-12	—	₹6 cr	-34.4%	0.0%	0.6x
2025-11	—	₹11 cr	-17.1%	0.0%	0.6x
2025-10	—	₹11 cr	-17.1%	0.0%	0.6x
2025-09	—	₹11 cr	-17.1%	0.0%	0.6x
2025-08	—	₹365 cr	-10.8%	0.0%	0.6x
2025-07	—	₹365 cr	-10.8%	0.0%	0.6x
2025-06	—	₹365 cr	-10.8%	0.0%	0.6x
2025-05	35.7x	₹806 cr	1.5%	6.0%	0.6x
2025-04	29.0x	₹806 cr	1.5%	6.0%	0.6x
2025-03	30.2x	₹806 cr	1.5%	6.0%	0.6x
2025-02	54.9x	₹1258 cr	1.0%	6.0%	0.6x
2025-01	70.6x	₹1258 cr	1.0%	6.0%	0.6x
2024-12	81.2x	₹1258 cr	1.0%	6.0%	0.6x
2024-11	119.8x	₹1650 cr	0.6%	6.0%	0.6x
2024-10	134.6x	₹1650 cr	0.6%	6.0%	0.6x
2024-09	144.8x	₹1650 cr	0.6%	6.0%	0.6x
2024-08	170.0x	₹1685 cr	0.5%	6.0%	0.6x
2024-07	138.0x	₹1685 cr	0.5%	6.0%	0.6x
2024-06	136.3x	₹1685 cr	0.5%	6.0%	0.6x
2024-05	—	₹1520 cr	-2.1%	0.0%	0.7x
2024-04	—	₹1520 cr	-2.1%	0.0%	0.7x
2024-03	—	₹1520 cr	-2.1%	0.0%	0.7x
2024-02	—	₹1520 cr	-2.1%	0.0%	0.7x
2024-01	—	₹1520 cr	-2.1%	0.0%	0.7x
2023-12	—	₹1520 cr	-2.1%	0.0%	0.7x
2023-11	—	₹1520 cr	-2.1%	0.0%	0.7x
2023-10	—	₹1520 cr	-2.1%	0.0%	0.7x
2023-09	—	₹1520 cr	-2.1%	0.0%	0.7x
2023-08	—	₹1520 cr	-2.1%	0.0%	0.7x
2023-07	—	₹1520 cr	-2.1%	0.0%	0.7x
2023-06	—	₹1520 cr	-2.1%	0.0%	0.7x
2023-05	15.0x	₹1665 cr	2.1%	5.0%	0.8x
2023-04	16.3x	₹1665 cr	2.1%	5.0%	0.8x
2023-03	14.2x	₹1665 cr	2.1%	5.0%	0.8x
2023-02	15.4x	₹1665 cr	2.1%	5.0%	0.8x
2023-01	18.1x	₹1665 cr	2.1%	5.0%	0.8x
2022-12	21.9x	₹1665 cr	2.1%	5.0%	0.8x
2022-11	18.8x	₹1665 cr	2.1%	5.0%	0.8x
2022-10	19.1x	₹1665 cr	2.1%	5.0%	0.8x
2022-09	18.8x	₹1665 cr	2.1%	5.0%	0.8x
2022-08	20.4x	₹1665 cr	2.1%	5.0%	0.8x
2022-07	21.3x	₹1665 cr	2.1%	5.0%	0.8x
2022-06	20.8x	₹1665 cr	2.1%	5.0%	0.8x
2022-05	—	₹1541 cr	-6.3%	3.0%	0.9x
2022-04	—	₹1541 cr	-6.3%	3.0%	0.9x
2022-03	—	₹1541 cr	-6.3%	3.0%	0.9x
2022-02	—	₹1541 cr	-6.3%	3.0%	0.9x
2022-01	—	₹1541 cr	-6.3%	3.0%	0.9x
2021-12	—	₹1541 cr	-6.3%	3.0%	0.9x
2021-11	—	₹1541 cr	-6.3%	3.0%	0.9x
2021-10	—	₹1541 cr	-6.3%	3.0%	0.9x
2021-09	—	₹1541 cr	-6.3%	3.0%	0.9x
2021-08	—	₹1541 cr	-6.3%	3.0%	0.9x
2021-07	—	₹1541 cr	-6.3%	3.0%	0.9x
2021-06	—	₹1541 cr	-6.3%	3.0%	0.9x
2021-05	21.9x	₹2363 cr	2.6%	8.0%	0.7x
2021-04	17.6x	₹2363 cr	2.6%	8.0%	0.7x
2021-03	13.1x	₹2363 cr	2.6%	8.0%	0.7x
2021-02	14.2x	₹2363 cr	2.6%	8.0%	0.7x
2021-01	14.4x	₹2363 cr	2.6%	8.0%	0.7x
2020-12	16.8x	₹2363 cr	2.6%	8.0%	0.7x
2020-11	12.9x	₹2363 cr	2.6%	8.0%	0.7x
2020-10	13.7x	₹2363 cr	2.6%	8.0%	0.7x
2020-09	16.0x	₹2363 cr	2.6%	8.0%	0.7x
2020-08	15.2x	₹2363 cr	2.6%	8.0%	0.7x
2020-07	14.6x	₹2363 cr	2.6%	8.0%	0.7x
2020-06	15.2x	₹2363 cr	2.6%	8.0%	0.7x
2020-05	6.2x	₹2779 cr	4.0%	10.0%	0.8x
2020-04	6.7x	₹2779 cr	4.0%	10.0%	0.8x
2020-03	4.6x	₹2779 cr	4.0%	10.0%	0.8x
2020-02	5.2x	₹2779 cr	4.0%	10.0%	0.8x
2020-01	6.4x	₹2779 cr	4.0%	10.0%	0.8x
2019-12	5.7x	₹2779 cr	4.0%	10.0%	0.8x
2019-11	6.0x	₹2779 cr	4.0%	10.0%	0.8x
2019-10	6.6x	₹2779 cr	4.0%	10.0%	0.8x
2019-09	6.2x	₹2779 cr	4.0%	10.0%	0.8x
2019-08	6.1x	₹2779 cr	4.0%	10.0%	0.8x
2019-07	6.5x	₹2779 cr	4.0%	10.0%	0.8x
2019-06	7.0x	₹2779 cr	4.0%	10.0%	0.8x
2019-05	8.2x	₹1874 cr	4.5%	9.0%	0.9x
2019-04	7.1x	₹1874 cr	4.5%	9.0%	0.9x
2019-03	7.4x	₹1874 cr	4.5%	9.0%	0.9x
2019-02	7.3x	₹1874 cr	4.5%	9.0%	0.9x
2019-01	7.8x	₹1874 cr	4.5%	9.0%	0.9x

Methodology and data notes